Quarterly Pricing Pulse — Q2 2026

AbbVie filed four material events in Q2 (April 29, May 12, June 22, plus earlier filings), each tied to Botox/Juvéderm and the Allē loyalty ecosystem. While the exact terms remain proprietary, the frequency and timing suggest AbbVie is defending market share against Jeuveau and Merz by deepening rebate/loyalty incentives. For medspa owners: expect lower net revenue per unit on Botox and Juvéderm unless you're hitting volume thresholds or bundling with other AbbVie products. Audit your Allē enrollment and rebate tiers now—if you're not maximizing loyalty rewards, you're leaving margin on the table. Consider whether volume-based pricing (e.g., discounting per-unit cost to drive higher case volume) makes sense for your patient base. Monitor competitor rebate cards and loyalty programs; they're the new battleground for patient acquisition and retention.

Evolus filed three material events in Q2 (March 13, May 4, June 12), each highlighting Jeuveau Rewards and direct medspa targeting. Jeuveau is positioning itself as the price-competitive botulinum toxin alternative, with rebate programs designed to undercut Botox on a per-unit or per-case basis. For medspa owners: if you haven't evaluated Jeuveau as a secondary or primary botulinum toxin, Q2's activity signals it's now a serious contender. Compare net cost-per-unit after rebates; Jeuveau's lower list price + aggressive loyalty incentives may improve your margin vs. Botox, even if patient perception lags. Test a small volume cohort to measure patient satisfaction and retention. Be cautious: Jeuveau's market share is still small, so supply and rebate sustainability are unproven. Diversifying your botulinum toxin portfolio (Botox + Jeuveau, or Botox + Merz NT 201) hedges pricing risk.

Hims & Hers filed three material events (May 21, June 2, June 15) signaling aggressive GLP-1 expansion; Eli Lilly filed four (April 30, May 7, May 20, plus earlier), hinting at supply/pricing and compounding-rule changes; Viking Therapeutics filed three (February 11, April 29, May 26) announcing VK2735, a next-gen dual-agonist pipeline competitor. For medspa owners offering cash-pay GLP-1: expect margin compression from telehealth competition and future supply shifts. Hims & Hers' telehealth model undercuts in-person medspa pricing by eliminating facility overhead. Eli Lilly's compounding-rule signals may restrict medspa sourcing or force reliance on branded products (Zepbound/Mounjaro), which carry higher acquisition costs. Viking's VK2735 pipeline threatens future supply diversity and pricing power. Action: audit your GLP-1 sourcing (compounded vs. branded), patient retention rates, and margin per case. If margins are thin (<20%), consider deprioritizing GLP-1 or bundling it with high-margin injectables/devices. Lock in supplier agreements now before pricing shifts.

Galderma completed a Restylane Lyft chin-augmentation trial (Q2 completed status) and launched a new chin-region trial (not-yet-recruiting), signaling label expansion and market segmentation. HarmonyCa (Allergan) completed a mid-face trial; multiple HA formulations (Cellbooster Shape, Dr. Korman HA 20 mg/mL, LMW-CL-HA) advanced through trials. For medspa owners: new filler indications (chin, mid-face, body) create upsell opportunities but don't immediately change pricing. Restylane Lyft's chin indication, once approved, may command a premium vs. off-label use—but competitive pressure from other HA fillers will cap price increases. Filler pricing remains stable this quarter; the real margin play is case bundling (e.g., lips + chin, or cheeks + mid-face) to increase average revenue per patient. Monitor trial completions for label changes; approved indications often come with reimbursement codes and insurance coverage, which can shift your payer mix and pricing strategy.

Apyx Medical (Renuvion) filed four material events (May 14, May 21, June 17, plus earlier), signaling active clinical and commercial activity in helium-plasma skin tightening and body contouring. Bausch Health (Solta: Thermage, Fraxel, Clear+Brilliant) filed four material events (March 2, April 29, May 19, plus earlier), hinting at potential M&A or spin-off activity. The Beauty Health Company (HydraFacial) filed three material events (May 12, June 16, June 22), reflecting facial-category demand and consumable/device support volatility. For medspa owners: device-category pricing and support are in flux. Renuvion's activity suggests growing adoption and potential price competition; Solta's M&A signals may disrupt service, pricing, and consumable supply. HydraFacial's repeated filings suggest either strong demand or internal restructuring—either way, consumable costs and device financing terms could shift. Action: if you own Renuvion, Thermage, or Fraxel, lock in consumable supply contracts and service agreements now. If you're considering device acquisition, wait for clarity on Solta's corporate structure before committing to Thermage/Fraxel. HydraFacial remains a stable consumable-revenue play, but monitor pricing and bundle-offer changes.

Payless Compounders, LLC issued a Class II recall for semaglutide-glycine-cyanocobalamin injectables (lack of sterility assurance), underscoring compounding-supply risk for medspas sourcing GLP-1 off-label. Eli Lilly's Q2 filings hinted at compounding-rule changes that could restrict medspa access to compounded formulations. For medspa owners: if you source compounded GLP-1, audit your supplier's FDA compliance, sterility protocols, and recall history immediately. Consider switching to branded Zepbound/Mounjaro (higher cost, but lower regulatory risk) or pausing GLP-1 offerings until supply clarity improves. Document all sourcing decisions and patient consent forms; regulatory scrutiny on medspa GLP-1 is rising. The recall is a canary in the coal mine—expect more compounding-supply disruptions as FDA oversight tightens.